Helixon Biotechnology (suzhou) Co., Ltd
Clinical trials sponsored by Helixon Biotechnology (suzhou) Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug HXN6005 tested in healthy volunteers for first time Results expected Mar 2027 (estimated)
- New eczema drug HXN5003 enters first human safety trial Results expected Mar 2027 (estimated)
-
Can a new injection calm severe eczema?
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called HXN5003 in healthy volunteers and in people with moderate-to-severe atopic dermatitis, a common form of eczema. The study first gives a single dose to healthy participants to check safety, then gives multiple doses to eczem…
Phase 1 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new injection quiet severe eczema?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called HXN6005 in healthy volunteers and in people with moderate-to-severe atopic dermatitis, a common form of eczema. The study is divided into three parts: first, healthy participants receive a single dose to check safety; …
Phase 1/2 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new injection plus a pill tame ulcerative colitis?
Disease control Not yet recruitingThis early trial is testing whether a new investigational drug called HX15001, given as an injection, can be safely combined with an existing pill (etrasimod) to treat moderate-to-severe ulcerative colitis. The study will include about 32 adults with the condition and will focus …
Phase 1 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New eczema drug HXN5003 enters first human safety trial
Symptom relief Not yet recruitingThis early-stage study tests a new drug called HXN5003 in 28 healthy adults to see if it is safe and how the body processes it. The drug is being developed for atopic dermatitis (eczema). Participants receive either the drug or a placebo, and researchers monitor for side effects …
Phase 1 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC